Skip to main content

RA/Inflammatory arthritis

RheumNow Podcast – ACR 2019  Round Up (11.15.19)
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.
  • #1223 ALLN-346 a urate degrading enzyme in a pig model of gout
  • #L06 Emapalumab for treating MAS in systemic JIA patients
  • #1890 and 2357 Methotrexate Safety from CIRT
  • #1240 Anakinra in acute gout – anaGO study
  • #2292, #2279 When to withdraw biologics in RA patients who become pregnant
  • #633, #631 Delays in referral of LBP
  • #196 VTE risk and future ASCVD risk
  • #2566 Polypharmacy
  • #860 EMBRACE – Belimumab in Blacks
High Dose Influenza Vaccine Under Age 65: Dr. David Liew

Dr. David Liew discusses abstract #2091 The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients presented at the 2019 ACR/ARP annual meeting in Atlanta. 

SJIA-associated ILD: Dr. Jonathan Hausmann

Dr. Hausmann describes a new inflammatory lung disease at the 2019 ACR/ARP annual meeting in Atlanta. 

Subcutaneous Biosimilar: Dr. Jonathan Kay

Dr. Kay highlights abstract #548 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush

Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Panel Presentation: Rheumatoid Arthritis

Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more. 

Studies on the Changing Face of RA: Dr. Janet Pope

Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta. 

Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew

Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta. 

The Risk RA Prospective Study: Dr. Jonathan Kay

Dr. Kay discusses abstract #1758 presented during a plenary session at the 2019 ACR/ARP annual meeting in Atlanta. 

MTX Withdraw after Starting JAK Inhibitors: Dr. Arthur Lau

Dr. Lau discusses abstract #1412 presented at the 2019 ACR/ARP Annual Meeting in Atlanta. 

Shoulder MRI for PMR: Dr. Paul Sufka

Dr. Sufka discusses abstract #1161 on Gadolinium-Enhanced MRI in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with PMR as presented at the 2019 ACR/ARP annual meeting in Atlanta.

SELECT-MONOTHERAPY Trial: Dr. Mike Putman

Dr. Mike Putman discusses his takeaway from the SELECT-MONOTHERAPY trial at the 2019 ACR/ARP annual meeting in Atlanta. 

Rituximab-Associated Hypogammaglobulinemia Rates: Dr. Janet Pope and Dr. Stefanie Wade

Drs. Janet Pope and Stefanie Wade discuss abstract #845 at the 2019 ACR/ARP annual meeting in Atlanta. 

Clinical Infection Risk and Safety Profile in RA: Dr. Kathryn Dao

Dr. Dao summarizes a number of studies presented on infection risk and safety profile in RA at the 2019 ACR/ARP annual meeting in Atlanta. 

Upadacitinib in RA: Dr. Cassandra Calabrese

Dr. Calabrese discusses abstract #547 and abstract #509 as presented at the ACR/ARP annual meeting in Atlanta. 

Will Reduction of RF Affect Erosions in RA? Dr. Janet Pope

Dr. Pope discusses Abstract #464 at the 2019 ACR/ARP annual meeting in Atlanta. 

Antimalarials in RA: Dr. Janet Pope

Dr. Pope discusses abstract #896 and abstract #1891 at the 2019 ACR/ARP annual meeting in Atlanta. 

MACE + VTE Across Multiple Upadacitinib Studies in RA: Dr. Jonathan Kay

Dr. Kay discusses abstract #846 presented at the ACR/ARP annual meeting in Atlanta. 

×